series-a
Stage
2021
Founded
1
Investors
About
Pheno Therapeutics is a clinical stage biotech company developing GPR17 antagonists for neurodegenerative and demyelinating disorders, focusing on therapeutically targeting oligodendrocytes to unlock the brain’s endogenous repair systems.
Explore Pheno Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.